Gynecologic Oncology Update
Avsnitt

TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

Gynecologic Oncology Update
Dela

Featuring an interview with Dr Ramez Eskander, including the following topics:

  • Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
  • Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
  • Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
  • Current and investigational targets of ADCs in gynecologic cancers (17:14)
  • Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
  • Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
  • Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
  • Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
  • Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)


CME information and select publications

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.